Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM
Key facts
- Who runs it
- Asian Institute of Gastroenterology, India
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 30 Apr 2025
- Expected to end
- 25 Dec 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Vonoprazan
- Esomeprazole 40mg
- Record updated
- 27 April 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Age ≥18 years
- History of POEM for achalasia
- Endoscopic confirmation of LA grade B, C, or D reflux esophagitis at 3 months post-POEM
- GERD symptoms (heartburn, regurgitation) for ≥4 weeks
- Willingness to provide informed consent and comply with study procedures
Who cannot take part
- History of prior anti-reflux surgery
- Regular use of NSAIDs, steroids, or anticoagulants affecting esophageal healing
- Presence of Barrett's esophagus, esophageal stricture, or malignancy
- Severe gastroparesis or esophageal motility disorder unrelated to achalasia
- Severe hepatic or renal impairment (ALT/AST >3× ULN, eGFR <30 mL/min)
- Pregnancy or breastfeeding
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Gerd
This trial is currently available in India.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Peroral Endoscopic Myotomy (POEM) is a well-established treatment for achalasia; however, it is frequently associated with gastroesophageal reflux disease (GERD), with many patients developing LA grade B or higher esophagitis. Proton pump inhibitors (PPIs) like Esomeprazole are the standard treatment, but Vonaprazan, a potassium-competitive acid blocker (P-CAB), offers superior acid suppression and may provide enhanced healing in post-POEM reflux esophagitis.
Read full original descriptionShow less
Primary Objective:
• To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks in patients receiving Vonaprazan 20 mg versus Esomeprazole 40 mg.
Secondary Objectives
* To assess improvement in reflux symptoms using the GERD-Q score at 8 weeks. * To evaluate the incidence of adverse events in each treatment group.
The 2 groups in the trial
- To assess the efficacy of vonapraprazon 20mg better than esomeprazole drugExisting treatment, for comparison
healing rate will be checked during endoscopy at 8 weeks
Treatment: Vonoprazan
- To see the healing rate of grade B esophagitisPlacebo, for comparison
healing rate will be checked during endoscopy at 8 weeks in patients receiving esomeprazole 40mg
Treatment: Esomeprazole 40mg
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT06955520, who can take part
- Record updated
- 27 April 2026